New Eye Health Warnings for Popular Diabetes Medications

November 9th, 2026
The U.S. Food and Drug Administration (FDA) has recently announced important updates regarding the use of GLP-1 medications, including popular drugs like Ozempic and Zepbound. These updates focus on a potential increased risk of a serious eye condition known as non-arteritic anterior ischemic optic neuropathy (NAION), which can lead to sudden and painless vision loss.

The FDA's announcement requires manufacturers of GLP-1 medications to revise the warnings and precautions sections of their product labels. This includes Eli Lilly’s Mounjaro and Novo Nordisk’s Ozempic and Wegovy, which are commonly used for managing weight and diabetes. While the exact cause of NAION is not fully understood, it is linked to decreased blood flow to the optic nerve.

Both Eli Lilly and Novo Nordisk have responded to the FDA's communication, emphasizing their commitment to patient safety. Novo Nordisk remains confident in the overall benefit-risk profile of their medications, despite the new warnings. The FDA’s evaluation involved a comprehensive review of clinical trial data, animal studies, and reports from healthcare providers.

Although the announcement may raise concerns among patients and investors, analysts suggest that the rarity of NAION, along with the significant health benefits provided by these medications, may help maintain confidence in their use. According to previous assessments, the risk of developing NAION may be low, affecting approximately 1 in 10,000 users of semaglutide, the active ingredient in Ozempic and Wegovy.

As always, it's essential for individuals using these medications to communicate openly with their healthcare providers. Discussing any potential risks and benefits can help ensure that patients make informed decisions about their treatment options. For further information on this topic, you can refer to updates from the European Medicines Agency regarding similar findings on this eye condition.

Helpful Links

Want more health and wellness content?

WellnessConnect publishes evidence-based articles every week, along with personalised programs for employers and their teams.

Browse all articles Get started with WellnessConnect